ASCO GU 2024 Prostate Cancer - Results from #60

Viewing 61-80 of 95 articles

ASCO GU 2024: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR of Prostate Cancer: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

ASCO GU 2024: Discussant: Unlocking Combination Therapy for mCRPC

ASCO GU 2024: Interim Analyses from the PROSPET-BX Trial: [68Ga]PSMA PET/CT vs. mpMRI in Patients with Suspicion of Prostate Cancer and Previous Negative Biopsy

ASCO GU 2024: Effect of Urinary Stagnation in the Prostatic Urethra on Generating False-Positive Midline Lesions on 18F-DCFPyL PSMA PET/CT

ASCO GU 2024: Renaming Gleason 3+3 (Grade Group 1): Against

ASCO GU 2024: Public Health Would Dramatically Improve if Gleason 6 (Grade Group 1) Weren’t Called Cancer

ASCO GU 2024: Patient-Provider Rurality and Outcomes in Older Men with Prostate Cancer

ASCO GU 2024: Systemic Treatment of High-Risk Biochemical Recurrence

ASCO GU 2024: Prostate Cancer Foundation (PCF) Screening Guidelines for Prostate Cancer in Black Men in the United States

ASCO GU 2024: Is There a Role for Stereotactic Radiotherapy in Selected Patients With Metastatic Castrate-Resistant Prostate Cancer?

ASCO GU 2024: Patient-Reported HRQoL in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate + Prednisone and Apalutamide After Radical Prostatectomy

ASCO GU 2024: Long-Term Results of Dose Escalation (80 vs 70 Gy) Combined with Long-Term Androgen Deprivation in High-Risk Prostate Cancer: GETUG-AFU 18 Randomized Trial

ASCO GU 2024: Building a Predictive Model for Outcomes with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer Using VISION Data: Preliminary Results

ASCO GU 2024: The Survival Outcomes for Men with Metastatic Castration-Resistant Prostate Cancer with and Without Homologous Recombination Deficiencies Treated with Radium-223: Princess Margaret Cancer Centre Experience

ASCO GU 2024: Barriers and Facilitators to First-Line Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer: The IMPLEMENT Study

ASCO GU 2024: Rate of Hospitalization and Length of Hospital Stay During and Post Docetaxel for Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer Using ARASENS

ASCO GU 2024: BRCAAway: A Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC Bearing HRR Mutations

ASCO GU 2024: CONTACT-02: Phase 3 Study of Cabozantinib + Atezolizumab vs Second Novel Hormonal Therapy in Patients with mCRPC

ASCO GU 2024: Estimating Median Overall Survival of Apalutamide Compared to Placebo in Metastatic Hormone-Sensitive Prostate Cancer Populations: Statistical Extrapolations of the TITAN Study

ASCO GU 2024: Homologous Recombination Repair Gene Mutation Testing Patterns and Treatment Selection from a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer

1
2
3
4
5